Cascade Drug-Release Strategy for Enhanced Anticancer Therapy

Zhang, Xu; Wang, Sheng; Cheng, Guohui; Yu, Peng; Chang, Jin; Chen, Xiaoyuan

doi:10.1016/j.matt.2020.10.002

Cited by 51 publications

(34 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In photo-responsive strategies, chemotherapeutic precision is still limited by the laser-focused range. 24 In TME-responsive strategies, the released drugs can still enter into normal cells via passive diffusion due to the lack of active targeting, inevitably killing them. 24 Therefore, intelligent nanotheranostics with precise spatiotemporal control over phototherapeutic and chemotherapeutic activities are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

The precise anti-tumor effect of a metallopolysaccharide-based nanotheranostic: turning phototherapy into programmed chemotherapy

Zhu

Guo

Yang

et al. 2022

Inorg. Chem. Front.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The precise anti-tumor effect of a metallopolysaccharide-based nanotheranostic: turning phototherapy into programmed chemotherapy

Zhu

Guo

Yang

et al. 2022

Inorg. Chem. Front.

View full text Add to dashboard Cite

show abstract

“…Since the prodrug strategy was initially recognized by Adrian Albert in 1958, it has provided various possibilities in the chemical design of existing cytotoxic drugs using biocompatible materials such as peptides, lipids, or amphipathic polymers [ 17 – 21 ]. As expected, prodrug strategy, as an increasingly versatile tool, is being used to address multiple barriers, including physicochemical, pharmacokinetic, or pharmacodynamics deficiencies of active agents that limit formulation inventions and generate uninspired biopharmaceutical performance [ 22 – 24 ]. Among them, stimuli-responsive prodrugs are more effective and desirable to realize accurate on-demand drug release and have been reported currently from various perspectives [ 25 – 28 ].…”

Section: Introductionmentioning

confidence: 99%

Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery

et al. 2022

View full text Add to dashboard Cite

A widely established prodrug strategy can effectively optimize the unappealing properties of therapeutic agents in cancer treatment. Among them, lipidic prodrugs extremely uplift the physicochemical properties, site-specificity, and antitumor activities of therapeutic agents while reducing systemic toxicity. Although great perspectives have been summarized in the progress of prodrug-based nanoplatforms, no attention has been paid to emphasizing the rational design of small-molecule lipidic prodrugs (SLPs). With the aim of outlining the prospect of the SLPs approach, the review will first provide an overview of conjugation strategies that are amenable to SLPs fabrication. Then, the rational design of SLPs in response to the physiological barriers of chemotherapeutic agents is highlighted. Finally, their biomedical applications are also emphasized with special functions, followed by a brief introduction of the promising opportunities and potential challenges of SLPs-based drug delivery systems (DDSs) in clinical application. Graphical Abstract

show abstract

“…Fortunately, light can be used as an external stimulus to control drug release because of its unique advantages such as safety, minimal cross-reaction, and spatiotemporal precision. − In particular, near-infrared (NIR) light could penetrate a few inches into tissues and display no apparent damage to tissues or cells . In addition, NIR light can be converted into heat using the photothermal conversion agents (PTCAs), thereafter triggering drug release from the nanocarriers through a thermal effect.…”

Section: Introductionmentioning

confidence: 99%

All-In-One Second Near-Infrared Light-Responsive Drug Delivery System for Synergistic Chemo-Photothermal Therapy

Zhou

Xie

Zhou

et al. 2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Light-responsive nanocarrier-based drug delivery systems (NDDSs), due to their unique advantages such as safety, minimal cross-reaction, and spatiotemporal precision, have received wide attention. Notably, second near-infrared (NIR-II) light, which has a high penetration depth for manipulating NDDSs to release drugs, is in high demand. Herein, polyethylene glycol (PEG)-modified hollow Cu x S nanoparticles (NPs) are developed as an all-in-one NIR-II light-responsive NDDS for synergistic chemo-photothermal therapy. First, Cu x S-PEG NPs were prepared under mild conditions by using Cu 2 O NPs as sacrificial templates. The morphology, photothermal effect, drug loading/releasing abilities, and synergistic chemo-photothermal therapy of Cu x S-PEG NPs have been investigated. The Cu x S-PEG NPs with hollow structures showed a high drug loading capacity (∼255 μg Dox per mg of Cu x S NPs) and stimuli-responsive drug release triggered by NIR-II laser irradiation. The synergistic chemo-photothermal therapy based on the Dox/Cu x S-PEG NPs showed 98.5% tumor elimination. Our study emphasizes the great potential of Cu x S-PEG NPs as an all-in-one NIR-II light-responsive NDDS for applications in biomedicine.

show abstract

Cascade Drug-Release Strategy for Enhanced Anticancer Therapy

Cited by 51 publications

References 124 publications

The precise anti-tumor effect of a metallopolysaccharide-based nanotheranostic: turning phototherapy into programmed chemotherapy

The precise anti-tumor effect of a metallopolysaccharide-based nanotheranostic: turning phototherapy into programmed chemotherapy

Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery

All-In-One Second Near-Infrared Light-Responsive Drug Delivery System for Synergistic Chemo-Photothermal Therapy

Contact Info

Product

Resources

About